This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
3 Medical Instruments Stocks to Buy Despite Industry Headwinds
by Urmimala Biswas
The Zacks Medical - Instruments industry is growing on R&D investments. ALC, STE and ABMD are set to gain the most. Yet, demand for non-COVID businesses is on the decline with the new COVID variant disrupting the trend.
Alcon (ALC) Stock Rallies 4.7% Since Posting Q4 Earnings Beat
by Zacks Equity Research
Alcon (ALC) stock rallies on robust growth across all Surgical and Vision Care sales categories.
Alcon's (ALC) Surgical Arm Rebounds, New Launches Aid Growth
by Zacks Equity Research
In Vision Care, Alcon (ALC) continues to see strong demand for PRECISION1 and PRECISION1 for Astigmatism, which are the company's newest contact lenses for the mainstream market.
Alcon (ALC) Publishes Dividend, New Board Member Addition Plans
by Zacks Equity Research
Alcon's 2022 AGM is set to take place in a closed format without the personal presence of shareholders.
Here's Why You Should Hold on to Alcon (ALC) Stock for Now
by Zacks Equity Research
Investors are optimistic about Alcon's (ALC) better-than-expected results and robust segmental performance.
Alcon (ALC) Expands in the U.S. With New Clareon IOLs Launch
by Zacks Equity Research
With the latest launch, Alcon's (ALC) Clarion Monofocal, Clareon PanOptix, Clareon PanOptix Toric, Clareon Vivity and Clareon Vivity Toric IOLs are now available in the United States.
Alcon (ALC) Surgical Arm Expands, International Growth Slows
by Zacks Equity Research
In Surgical, Alcon (ALC) remains the market leader in presbyopia correcting IOLs on the strength of both PanOptix and Vivity.
Alcon's (ALC) Q4 Earnings Top Estimates, Margins Increase
by Zacks Equity Research
According to Alcon (ALC), strong product flow results in above-market revenue growth, which drives core operating leverage and margin expansion.
Alcon's (ALC) Global Growth Solid, New Lenses Sales Rise
by Zacks Equity Research
Alcon's (ALC) new contact lenses are gaining market share and the Systane brand family has been posting strong double-digit growth in all regions.
Alcon (ALC) Launches Preservative-Free Drops for Dry Eye Relief
by Zacks Equity Research
Alcon's (ALC) new preservative-free solution for patients with dry eye symptoms is the latest addition to its leading global artificial tear brand Systane.
Alcon (ALC) Vision Care Sales Grow Despite Supply Disruption
by Zacks Equity Research
Alcon's (ALC) new contact lenses are gaining market share and the Systane brand family has been posting strong double-digit growth in all regions.
Here's Why You Should Hold on to Alcon (ALC) Stock for Now
by Zacks Equity Research
Investors are optimistic about Alcon's (ALC) better-than-expected third-quarter results and robust performance by the Vision Care arm.
Alcon (ALC) on Track With Successful Global PRECISION1 Rollout
by Zacks Equity Research
Alcon (ALC) enhances contact lens experience, especially for new wearers, with the continued successful rollout of PRECISION1.
Alcon (ALC) Surgical Arm Grows Amid Global Trade Disruption
by Zacks Equity Research
Segment wise, within Alcon's (ALC) Surgical arm, the portfolio of advanced technology intraocular lenses is driving increased penetration rates of ATIOLs.
Alcon (ALC) Q3 Earnings Beat Estimates, Margin Improves
by Zacks Equity Research
Alcon (ALC) records year-over-year growth across all sales categories in Surgical and Vision Care in Q3.
Abbott's (ABT) Organic Sales Grow Amid Spike in COVID Cases
by Zacks Equity Research
Within Nutrition, the robust year-over-year performance of Abbott's (ABT) U.S. pediatric and international adult nutrition arms drives the company in the third quarter.
STERIS (STE) Hits a New 52-Week High: What's Driving It?
by Zacks Equity Research
Strong performance by the Healthcare, AST and Life Sciences segments is driving the top line for STERIS (STE).
Insulet's (PODD) Omnipod Sales Grow on New Product Upgrade
by Zacks Equity Research
Insulet (PODD) adds significant capacity in preparation for the Omnipod 5 launch in 2021.
Here's Why You Should Retain Bio-Rad (BIO) Stock For Now
by Zacks Equity Research
Investors are optimistic about Bio-Rad (BIO) on solid international market performance and raised 2021 guidance.
QIAGEN (QGEN) New Launch to Aid Global TB Elimination Targets
by Zacks Equity Research
QIAGEN's (QGEN) QIAreach QuantiFERON-TB test is now accessible in high burden, low-resource regions.
Abbott's (ABT) Nutrition Arm in Focus on Real Madrid Alliance
by Zacks Equity Research
According to Abbott (ABT), the partnership is set to support education, sports and social welfare activities of at-risk children in 80 countries.
Charles River (CRL) to Offer Cryo-EM Capabilities With New Pact
by Zacks Equity Research
Charles River's (CRL) recent partnership will enable the company to improve drug discovery projects by allowing structure-based design for a greater portfolio of targets.
Here's Why You Should Invest In Henry Schein (HSIC) Now
by Zacks Equity Research
Investors continue to be optimistic about Henry Schein (HSIC) on its extensive global foothold and raised 2021 earnings guidance.
NuVasive (NUVA) Announces Two Developments in Cohere TLIF Line
by Zacks Equity Research
According to NuVasive (NUVA), Porous PEEK is a clear differentiator for the company in the market.
Hologic (HOLX) to Expand Surgical Portfolio With Bolder Buyout
by Zacks Equity Research
Hologic's (HOLX) recent acquisition will accelerate its growth and enhance patient outcomes by leveraging significant commercial resources and strong relationships with OB/GYN specialists.